Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.710
-0.010 (-0.21%)
At close: Mar 10, 2026, 4:00 PM EDT
4.800
+0.090 (1.91%)
After-hours: Mar 10, 2026, 7:58 PM EDT
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $529.00K in the quarter ending September 30, 2025, a decrease of -60.49%. This brings the company's revenue in the last twelve months to $14.61M, up 116.64% year-over-year. In the year 2024, Arbutus Biopharma had annual revenue of $6.17M, down -65.98%.
Revenue (ttm)
$14.61M
Revenue Growth
+116.64%
P/S Ratio
62.02
Revenue / Employee
$331,955
Employees
44
Market Cap
905.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
| Dec 31, 2019 | 6.01M | 66.00K | 1.11% |
| Dec 31, 2018 | 5.95M | -4.76M | -44.44% |
| Dec 31, 2017 | 10.70M | 9.21M | 617.64% |
| Dec 31, 2016 | 1.49M | -21.79M | -93.59% |
| Dec 31, 2015 | 23.28M | 8.32M | 55.66% |
| Dec 31, 2014 | 14.95M | -512.00K | -3.31% |
| Dec 31, 2013 | 15.47M | 1.36M | 9.64% |
| Dec 31, 2012 | 14.11M | -2.71M | -16.10% |
| Dec 31, 2011 | 16.81M | -4.62M | -21.54% |
| Dec 31, 2010 | 21.43M | 7.66M | 55.67% |
| Dec 31, 2009 | 13.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Valneva SE | 211.09M |
| Maravai LifeSciences Holdings | 185.74M |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| ARS Pharmaceuticals | 84.28M |
| Evommune | 13.00M |
| KalVista Pharmaceuticals | 1.43M |
ABUS News
- 7 days ago - Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant - WSJ
- 7 days ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 7 days ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 7 days ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 7 days ago - Moderna Resolves Global Patent Litigation with Arbutus/Genevant - Accesswire
- 5 weeks ago - Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts - Seeking Alpha
- 4 months ago - Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 - GlobeNewsWire